GYS1 and glycogen storage disease II: GYS1 has emerged as a therapeutic target for several glycogen storage diseases (GSD), including GSD type II (Pompe disease)23, GSD type IV (Andersen disease and adult polyglucosan body disease)24 and Lafora disease25.